The 8 analysts offering 12-month price forecasts for TCR2 Therapeutics Inc have a median target of 10.50, with a high estimate of 20.00 and a low estimate of 2.00. The median estimate represents a +683.58% increase from the last price of 1.34.
The current consensus among 8 polled investment analysts is to Buy stock in TCR2 Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.74
Reporting Date Apr 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.